News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No news articles were published in the past hour; no fresh market-moving headlines.
  • No major geopolitical, economic, or corporate developments reported in the last hour.
  • Trading will rely on preexisting trends and scheduled data until new headlines emerge.
  • Volatility is likely to remain muted in the absence of fresh information.
  • Traders are likely to maintain positions until scheduled releases or corporate reports provide direction.
  • Hour produced no new information to materially alter market consensus.

Latest Articles

XTEND Secures $8.25 Million Order, Marking Continued Expansion of Autonomous Drone Programs Across Europe

XTEND Secures $8.25 Million Order, Marking Continued Expansion of Autonomous Drone Programs Across Europe

XTEND, a software and AI robotics leader under JFB Construction Holdings, secured an $8.25 million order from a European defense customer for advanced autonomous drone systems supporting indoor and tactical strike operations. These deployments reflect growing defense adoption of autonomous systems, backed by XTEND's proprietary technology. The deve…

EverQuote to Present at Upcoming Investor Conferences

EverQuote to Present at Upcoming Investor Conferences

EverQuote, Inc., a Nasdaq-listed AI-powered growth solutions provider for the property and casualty insurance sector, announced its management team will participate in several upcoming investor conferences in May and June 2026. The events include presentations and one-on-one meetings at significant industry conferences across New York, California, …

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Cadrenal Therapeutics reported Q1 2026 financial results and disclosed progress in the development of CAD-1005, a first-in-class 12-LOX inhibitor for treating heparin-induced thrombocytopenia (HIT). Following FDA End-of-Phase 2 meeting feedback, the company plans to initiate a randomized, blinded, placebo-controlled Phase 3 registration trial, aimi…

Live Ventures to Issue Fiscal Second Quarter 2026 Financial Results and Hold Earnings Conference Call on May 14, 2026

Live Ventures to Issue Fiscal Second Quarter 2026 Financial Results and Hold Earnings Conference Call on May 14, 2026

Live Ventures Incorporated, a diversified holding company focused on value-oriented acquisitions of domestic middle-market companies, will release its fiscal second quarter 2026 financial results on May 14, 2026. The company will hold an earnings conference call the same day to discuss results. The company operates a diverse portfolio spanning text…

Weatherford Awarded Managed Pressure Drilling Contract by Ventura Offshore for Operations in Brazil

Weatherford Awarded Managed Pressure Drilling Contract by Ventura Offshore for Operations in Brazil

Weatherford International plc has been awarded a managed pressure drilling contract by Ventura Offshore Holding Ltd to provide a comprehensive MPD solution for the SSV Victoria drilling rig in Brazil's Búzios Field. The contract includes delivery of the G3 Integrated Riser Joint MPD system, rig preparation, system integration, and long-term afterma…

Devon Energy and Coterra Energy Complete Merger

Devon Energy and Coterra Energy Complete Merger

Devon Energy Corporation and Coterra Energy Inc. have completed an all-stock merger, creating a leading U.S. shale producer with a strong asset base, particularly in the Delaware Basin. The combined company will retain the Devon Energy name and ticker (DVN) and is targeting $1 billion in annual cost synergies by the end of 2027. The merger position…

Prenetics’ IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership

Prenetics’ IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership

Prenetics Global Limited, trading as PRE on NASDAQ, announced a multi-year exclusive partnership between its premium health brand IM8 and Major League Soccer club Inter Miami CF. The deal includes IM8 becoming the exclusive official health supplements partner of the club, placement of IM8 products in the team's daily routines, branding opportunitie…

SS Innovations Demonstrates Long-Distance Telesurgery Capabilities at Royal Australian College of Surgeons Annual Scientific Congress

SS Innovations Demonstrates Long-Distance Telesurgery Capabilities at Royal Australian College of Surgeons Annual Scientific Congress

SS Innovations International, Inc. announced the successful completion of a long-distance telesurgery spanning more than 4,500 miles, using their proprietary SSi Mantra surgical robotic system and the portable SSi MantrAsana tele-surgeon console. The procedure was performed remotely from Australia to India during the Royal Australian College of Sur…

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

Oragenics, Inc. announced a Letter of Intent to license CardioDialysis™ technology from Sigyn Therapeutics to develop treatments for traumatic brain injury (TBI) and related neurodegenerative diseases. This technology complements Oragenics' ongoing Phase IIa trial of ONP-002 by targeting systemic inflammation outside the brain, potentially creating…

Drone Makers ACSL and Draganfly Partner to Bring NDAA-Compliant Japanese Drones to Canadian Market; Signs Exclusive Distributor Agreement and Launches Technology Integration

Drone Makers ACSL and Draganfly Partner to Bring NDAA-Compliant Japanese Drones to Canadian Market; Signs Exclusive Distributor Agreement and Launches Technology Integration

Draganfly Inc. has signed an exclusive master distributor agreement with ACSL, the largest Japanese drone maker, to introduce ACSL's NDAA-compliant SOTEN drone platform to the Canadian market. This collaboration enables cross-platform interoperability, allowing drones from both companies to share payloads and control systems, expanding capabilities…

MARA Announces Launch of Consent Solicitation for the 8.750% Senior Secured Notes due 2032 of Long Ridge Energy LLC

MARA Announces Launch of Consent Solicitation for the 8.750% Senior Secured Notes due 2032 of Long Ridge Energy LLC

MARA Holdings, Inc. announced a consent solicitation to amend the indenture governing Long Ridge Energy LLC's 8.750% Senior Secured Notes due 2032. This is part of MARA's planned acquisition of Long Ridge Energy & Power LLC, aiming to avoid a change of control event under the note indenture. The solicitation seeks bondholders' consent to amend term…

Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption

Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption

Milestone Scientific (NYSE: MLSS) announced progress on expanding its CompuFlo® medical business, including growth of an Advisor Program driving physician utilization, regional expansion into Medicare and commercial payer jurisdictions, and partnerships with academic institutions for clinical validation. The company is building out its sales presen…

Innventure to Announce First Quarter 2026 Results on May 14, 2026

Innventure to Announce First Quarter 2026 Results on May 14, 2026

Innventure, Inc., an industrial growth conglomerate focused on commercializing breakthrough technologies, announced it will release its first quarter 2026 financial results after market close on May 14, 2026. The company will host a conference call to discuss the results, which will be webcast live and available for replay on its investor relations…

European Gas Slides as Diplomatic Moves Raise Hopes for Iran Peace Accord

European Gas Slides as Diplomatic Moves Raise Hopes for Iran Peace Accord

European natural gas benchmarks eased Thursday as market participants monitored reports that Washington and Tehran are engaging mediators on a one-page framework to revive peace talks. The Dutch TTF front-month contract fell modestly, as did the U.K. front-month, while officials on both sides signalled differing reactions to the U.S. proposal. Anal…

Mexico's annual inflation slows to 4.45% in April, under forecasts

Mexico's annual inflation slows to 4.45% in April, under forecasts

Mexico's headline inflation fell to 4.45% in April from 4.59% in March, coming in marginally below economist forecasts. Core inflation, which strips out food and energy, eased to 4.26% from 4.45% and was slightly under expectations. The central bank, Banxico, is due to announce its policy move Thursday after an unexpected rate cut in March, while m…

Melia Sees Strong Domestic Demand as Middle East Conflict Redirects Tourists

Melia Sees Strong Domestic Demand as Middle East Conflict Redirects Tourists

Melia Hotels expects robust sales in Spain this summer as geopolitical tensions in the Middle East prompt travelers to alter plans toward Mediterranean and Caribbean destinations. CEO Gabriel Escarrer told shareholders that bookings at the group's luxury resorts and urban hotels in Spain are rising in double digits, and the company has lifted its E…

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

AIM ImmunoTech announced a 50% Objective Response Rate in a Phase 2 clinical trial conducted by UPMC, testing their drug Ampligen in combination with checkpoint inhibitors and chemotherapy for recurrent ovarian cancer. The trial showed durable responses, clinical benefit, and no severe toxicities, indicating Ampligen's potential to enhance immunoth…